Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
An innovative biopharmaceutical company is seeking a Global Labelling Strategist to lead the development of labeling strategies for its pipeline of antibody therapeutics. This role involves working closely with cross-functional teams to ensure compliance with regulations and to support the creation of product labels. The ideal candidate will have a strong background in biologics and regulatory affairs, along with excellent analytical and critical thinking skills. This is a unique opportunity to contribute to the advancement of groundbreaking therapies that aim to improve the lives of patients suffering from severe autoimmune diseases and cancer.
Global Labelling Strategist
Apply locations: Belgium - Remote, Boston, MA, USA
Time type: Full time
Posted on: Posted 3 Days Ago
Job requisition id: REQ-3251
argenx is a clinical-stage biopharmaceutical company that is creating and developing a pipeline of differentiated antibody therapeutics. Our unique antibody engineering technologies combined with the complementary expertise of our people enabled us to build a clinical-stage portfolio of novel product candidates – tailored from discovery through development to address patient needs.
Purpose of the position:
Within regulatory affairs and in cross-functional teams, lead the labeling development of one asset, supervise Target Product Label initiative across argenx portfolio and, when needed, contribute to the labeling strategy of other assets.
Key Accountabilities/Responsibilities:
Desired Skills and Experience:
About Us:
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland.